Runjhun Bhatia, MD
Neurology · Indianapolis, INNPI 1427440718
Payments from drug & device makers
Across 89 payments — averaging $23.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$411
- Neurocrine Biosciences, Inc.$195
- Takeda Pharmaceuticals U.S.A., Inc.$155
- SK Life Science, Inc.$125
- Vanda Pharmaceuticals Inc.$117
- Pfizer$106
- plus $939 from 23 others
What the payments were for
- Food & beverage$2,048100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $411 |
| Neurocrine Biosciences, Inc. | 9 | $195 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $155 |
| SK Life Science, Inc. | 4 | $125 |
| Vanda Pharmaceuticals Inc. | 4 | $117 |
| Pfizer | 5 | $106 |
| Jazz Pharmaceuticals Inc. | 2 | $87 |
| Argenx US, Inc. | 4 | $82 |
| Catalyst Pharmaceuticals, Inc. | 3 | $75 |
| Amgen | 4 | $67 |
| UCB, Inc. | 2 | $61 |
| Lundbeck LLC | 2 | $55 |
| CSL Behring | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $47 |
| Eisai Inc. | 2 | $43 |
| Novartis | 2 | $43 |
| Alnylam Pharmaceuticals Inc. | 1 | $37 |
| Neurelis, Inc. | 2 | $32 |
| Genentech USA, Inc. | 1 | $32 |
| Livanova USA, Inc. | 1 | $27 |
| TG Therapeutics, Inc. | 1 | $26 |
| Cala Health, Inc. | 1 | $24 |
| Aucta Pharmaceuticals, Inc. | 1 | $23 |
| Cycle Pharmaceuticals Inc | 1 | $21 |
| Biogen | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
How this compares
$2,048 in reported general payments places this provider in the 45th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 23 | $2,446 |
| Levetiracetam | 73 | $1,742 |
| Lamotrigine | 45 | $705 |
| Gabapentin | 20 | $189 |
| Donepezil Hcl | 11 | $106 |
Paid to pharmacies, not to this prescriber.
Other neurology in Indianapolis
- Kristi GeorgeIndianapolis$10.8M
- Craig HerrmanIndianapolis$7.8M
- Martin FarlowIndianapolis$4.8M
- Jared BroschIndianapolis$4.7M
- Alexandru BarboiIndianapolis$1.9M
- Kathryn NevelIndianapolis$1M
- Liana ApostolovaIndianapolis$990K
- Robert PascuzziIndianapolis$582K
- Adam ComerIndianapolis$382K
- Cynthia BodkinIndianapolis$377K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.